These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37385337)

  • 21. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial.
    O'Byrne PM; Woodcock A; Bleecker ER; Bateman ED; Lötvall J; Forth R; Medley H; Jacques L; Busse WW
    Respir Res; 2014 Aug; 15(1):88. PubMed ID: 25108545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal Model-Based Meta-Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma.
    Yang S; Simeoni M; Beerahee M
    Clin Pharmacol Ther; 2022 Jun; 111(6):1286-1295. PubMed ID: 35271735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
    Ismaila AS; Birk R; Shah D; Zhang S; Brealey N; Risebrough NA; Tabberer M; Zhu CQ; Lipson DA
    Adv Ther; 2017 Sep; 34(9):2163-2172. PubMed ID: 28875459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.
    Gross AS; Goldfrad C; Hozawa S; James MH; Clifton CS; Sugiyama Y; Jacques L
    BMC Pulm Med; 2015 Dec; 15():165. PubMed ID: 26704701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
    Bansal S; Anderson M; Anzueto A; Brown N; Compton C; Corbridge TC; Erb D; Harvey C; Kaisermann MC; Kaye M; Lipson DA; Martin N; Zhu CQ; Papi A
    NPJ Prim Care Respir Med; 2021 May; 31(1):29. PubMed ID: 34035312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
    Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between handheld and clinic-based spirometry measurements in asthma patients receiving beclomethasone.
    Kerwin EM; Hickey L; Small CJ
    Respir Med; 2019 May; 151():35-42. PubMed ID: 31047115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
    Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma.
    Longphre MV; Getz EB; Fuller R
    Ann Am Thorac Soc; 2017 Feb; 14(2):182-189. PubMed ID: 27849125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
    Chan R; Sousa AR; Mallett S; Hynds P; Homayoun-Valiani F; Tabberer M; Mehta R
    Pulm Pharmacol Ther; 2016 Dec; 41():19-24. PubMed ID: 27599598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
    Rodrigo GJ; Plaza V
    Ann Allergy Asthma Immunol; 2016 Jun; 116(6):565-70. PubMed ID: 27117053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-term effects of fluticasone furoate/vilanterol in exercising asthmatic adolescents: A randomized and open label trial.
    Bar-Yoseph R; Gur M; Zuckerman S; Gut G; Hanna M; Toukan Y; Nir V; Masarweh K; Bentur L
    Basic Clin Pharmacol Toxicol; 2021 Nov; 129(5):369-375. PubMed ID: 34359097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
    Lipson DA; Barnacle H; Birk R; Brealey N; Locantore N; Lomas DA; Ludwig-Sengpiel A; Mohindra R; Tabberer M; Zhu CQ; Pascoe SJ
    Am J Respir Crit Care Med; 2017 Aug; 196(4):438-446. PubMed ID: 28375647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
    Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
    COPD; 2018; 15(4):334-340. PubMed ID: 30265816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
    Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
    Calverley PMA; Anderson JA; Brook RD; Crim C; Gallot N; Kilbride S; Martinez FJ; Yates J; Newby DE; Vestbo J; Wise R; Celli BR;
    Am J Respir Crit Care Med; 2018 Jan; 197(1):47-55. PubMed ID: 28737971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.
    Rodriguez-Roisin R; Tetzlaff K; Watz H; Wouters EF; Disse B; Finnigan H; Magnussen H; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1973-81. PubMed ID: 27578972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.